Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Towards treatment planning of COVID-19 : Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy

Year of Publication: 2020
Contained in: International immunopharmacology Vol. 84 (2020), p. 106560
All journal articles: Search for all articles in this journal
Language: English
Contributors: Saghazadeh, Amene | Author
Rezaei, Nima
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Corticosteroids
Immunoglobulin
Interleukin 6
Journal Article
Review
Targeted therapy
Treatment
Additional Keywords: *Betacoronavirus
Adrenal Cortex Hormones
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Coronavirus Infections
Humans
Immunoglobulins
Immunosuppressive Agents
Interleukin-6
Pandemics
Pneumonia, Viral
ISSN: 1878-1705
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 18.06.2020
Date Revised 18.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32413736
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.intimp.2020.106560
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04261nma a2200853 c 4500
001 NLM310833604
003 DE-601
005 20200619213930.0
007 cr uuu---uuuuu
008 200516s2020 000 0 eng d
024 7 |a 10.1016/j.intimp.2020.106560  |2 doi 
028 5 2 |a pubmed20n1237.xml 
035 |a S1567-5769(20)31029-8 
035 |a (DE-599)NLM32413736 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Saghazadeh, Amene 
245 1 0 |a Towards treatment planning of COVID-19  |h Elektronische Ressource  |b Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids 
300 |a Online-Ressource 
500 |a Date Completed 18.06.2020 
500 |a Date Revised 18.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier B.V. All rights reserved. 
520 |a The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Adrenal Cortex Hormones  |6 D000305  |a *therapeutic use  |6 Q000627 
653 2 |a Antibodies, Anti-Idiotypic  |6 D000888  |a *therapeutic use  |6 Q000627 
653 2 |a Antibodies, Monoclonal  |6 D000911  |a therapeutic use  |6 Q000627 
653 2 |a *Betacoronavirus  |6 D000073640 
653 2 |a Coronavirus Infections  |6 D018352  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Humans  |6 D006801 
653 2 |a Immunoglobulins  |6 D007136  |a *therapeutic use  |6 Q000627 
653 2 |a Immunosuppressive Agents  |6 D007166  |a *therapeutic use  |6 Q000627 
653 2 |a Interleukin-6  |6 D015850  |a immunology  |6 Q000276 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
655 7 |a COVID-19  |2 gnd 
655 7 |a Corticosteroids  |2 gnd 
655 7 |a Immunoglobulin  |2 gnd 
655 7 |a Interleukin 6  |2 gnd 
655 7 |a Targeted therapy  |2 gnd 
655 7 |a Treatment  |2 gnd 
655 7 |a Adrenal Cortex Hormones  |2 gnd 
655 7 |a Antibodies, Anti-Idiotypic  |2 gnd 
655 7 |a Antibodies, Monoclonal  |2 gnd 
655 7 |a Immunoglobulins  |2 gnd 
655 7 |a Immunosuppressive Agents  |2 gnd 
655 7 |a Interleukin-6  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Corticosteroids 
689 1 2 |a Immunoglobulin 
689 1 3 |a Interleukin 6 
689 1 4 |a Targeted therapy 
689 1 5 |a Treatment 
689 1 |5 DE-601 
689 2 0 |a Adrenal Cortex Hormones 
689 2 1 |a Antibodies, Anti-Idiotypic 
689 2 2 |a Antibodies, Monoclonal 
689 2 3 |a Immunoglobulins 
689 2 4 |a Immunosuppressive Agents 
689 2 5 |a Interleukin-6 
689 2 |5 DE-601 
700 1 |a Rezaei, Nima 
773 0 8 |i in  |t International immunopharmacology  |g Vol. 84 (2020), p. 106560  |q 84<106560  |w (DE-601)NLM112642683  |x 1878-1705 
856 4 1 |u http://dx.doi.org/10.1016/j.intimp.2020.106560  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 84  |j 2020  |b 13  |c 07  |h 106560